Literature DB >> 12499224

Activities of the glycylcycline tigecycline (GAR-936) against 1,924 recent European clinical bacterial isolates.

D Milatovic1, F-J Schmitz, J Verhoef, A C Fluit.   

Abstract

The in vitro activities of tigecycline against 1,924 clinical isolates were examined. The new glycylcycline exhibited excellent activity against all gram-positive cocci (MICs at which 90% of the isolates tested were inhibited [MIC(90)s], <or=1 microg/ml). In addition, it was also very potent against most members of the Enterobacteriaceae, with most MIC(90)s being <or=2 microg/ml. Among the nonfermenters, Acinetobacter spp. and Stenotrophomonas maltophilia are included in the in vitro spectrum of tigecycline activity.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12499224      PMCID： PMC149011          DOI： 10.1128/AAC.47.1.400-404.2003

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  16 in total

1.  Resistance to tetracycline and distribution of tetracycline resistance genes in European Staphylococcus aureus isolates.

Authors:  F J Schmitz; A Krey; R Sadurski; J Verhoef; D Milatovic; A C Fluit
Journal:  J Antimicrob Chemother       Date:  2001-02       Impact factor: 5.790

2.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates.

Authors:  A C Gales; R N Jones
Journal:  Diagn Microbiol Infect Dis       Date:  2000-01       Impact factor: 2.803

3.  In vitro activities of the glycylcycline GAR-936 against gram-positive bacteria.

Authors:  H W Boucher; C B Wennersten; G M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2000-08       Impact factor: 5.191

4.  Comparative in vitro activities of GAR-936 against aerobic and anaerobic animal and human bite wound pathogens.

Authors:  E J Goldstein; D M Citron; C V Merriam; Y Warren; K Tyrrell
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

5.  In vitro activity of GAR-936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae.

Authors:  R Patel; M S Rouse; K E Piper; J M Steckelberg
Journal:  Diagn Microbiol Infect Dis       Date:  2000-11       Impact factor: 2.803

6.  GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: preliminary guidelines and interpretive criteria.

Authors:  L M Deshpande; A C Gales; R N Jones
Journal:  Int J Antimicrob Agents       Date:  2001-07       Impact factor: 5.283

7.  Synthesis and structure-activity relationship of novel glycylcycline derivatives leading to the discovery of GAR-936.

Authors:  P E Sum; P Petersen
Journal:  Bioorg Med Chem Lett       Date:  1999-05-17       Impact factor: 2.823

8.  Susceptibilities of Mycoplasma hominis, M. pneumoniae, and Ureaplasma urealyticum to GAR-936, dalfopristin, dirithromycin, evernimicin, gatifloxacin, linezolid, moxifloxacin, quinupristin-dalfopristin, and telithromycin compared to their susceptibilities to reference macrolides, tetracyclines, and quinolones.

Authors:  G E Kenny; F D Cartwright
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

9.  In vivo pharmacodynamic activities of two glycylcyclines (GAR-936 and WAY 152,288) against various gram-positive and gram-negative bacteria.

Authors:  M L van Ogtrop; D Andes; T J Stamstad; B Conklin; W J Weiss; W A Craig; O Vesga
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

10.  Therapeutic efficacy of GAR-936, a novel glycylcycline, in a rat model of experimental endocarditis.

Authors:  T M Murphy; J M Deitz; P J Petersen; S M Mikels; W J Weiss
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191
View more
  27 in total

1.  [New antimicrobial drugs: an update].

Authors:  Heinz Burgmann
Journal:  Wien Med Wochenschr       Date:  2003

2.  In vitro activities of tigecycline (GAR-936) and 12 other antimicrobial agents against 90 Eikenella corrodens clinical isolates.

Authors:  Emilia Cercenado; Sonia Cercenado; Emilio Bouza
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

3.  Comparative in vitro susceptibilities of 396 unusual anaerobic strains to tigecycline and eight other antimicrobial agents.

Authors:  Ellie J C Goldstein; Diane M Citron; C Vreni Merriam; Yumi A Warren; Kerin L Tyrrell; Helen T Fernandez
Journal:  Antimicrob Agents Chemother       Date:  2006-08-28       Impact factor: 5.191

Review 4.  Tigecycline.

Authors:  James E Frampton; Monique P Curran
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Effect of medium age and supplementation with the biocatalytic oxygen-reducing reagent oxyrase on in vitro activities of tigecycline against recent clinical isolates.

Authors:  Peter J Petersen; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

6.  Pharmacokinetics of tigecycline after single and multiple doses in healthy subjects.

Authors:  Gopal Muralidharan; Marlynne Micalizzi; John Speth; Donald Raible; Steven Troy
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

7.  Diagnostic PCR analysis of the occurrence of methicillin and tetracycline resistance genes among Staphylococcus aureus isolates from phase 3 clinical trials of tigecycline for complicated skin and skin structure infections.

Authors:  C Hal Jones; Margareta Tuckman; Anita Y M Howe; Mark Orlowski; Stanley Mullen; Karen Chan; Patricia A Bradford
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

8.  Superinfection during treatment of nosocomial infections with tigecycline.

Authors:  E García-Cabrera; M E Jiménez-Mejías; M V Gil Navarro; M J Gómez-Gómez; C Ortiz-Leyba; E Cordero; J Pachón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-05-16       Impact factor: 3.267

9.  In vitro activity of tigecycline against multidrug-resistant Acinetobacter baumannii and selection of tigecycline-amikacin synergy.

Authors:  Ellen S Moland; David W Craft; Seong-geun Hong; Soo-young Kim; Lucas Hachmeister; Shimon D Sayed; Kenneth S Thomson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-02       Impact factor: 5.191

10.  Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.

Authors:  María-Isabel Morosini; María García-Castillo; Teresa M Coque; Aránzazu Valverde; Angela Novais; Elena Loza; Fernando Baquero; Rafael Cantón
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.